T&S delivered validated automation and industrial IT for a new injectable-drug production line, integrating Rockwell systems, HMI/visualisation and process simulation.
Pharmaceutical manufacturers face pressure to scale production while maintaining strict quality, compliance and efficiency. To support the launch of a new injectable-drug production line, a global pharmaceutical company partnered with T&S to strengthen its automation and industrial-IT environment, delivering validated automation systems for large-scale manufacturing of therapies targeting gastroenterology, diabetes and obesity.
The client, a major international pharmaceutical company, was investing in a new high-capacity line for injectable therapies - a large-scale program with significant operational complexity, multiple stakeholders and ambitious production-readiness objectives, requiring robust automation ensuring process reliability, traceability and continuity within a regulated framework.
T&S applied a multidisciplinary approach across automation integration, industrial IT and production-system validation. The teams ran workflow and process-simulation activities to optimise flows and anticipate constraints before deployment, integrated Rockwell automation systems for reliable coordination between equipment and supervisory systems, and developed HMI and visualisation software adapted to the line to improve operational monitoring and operator efficiency. T&S then contributed to system validation and commissioning to ensure production readiness and support manufacturing startup within the regulated environment.
The project highlights T&S's expertise in industrial automation and industrial IT for regulated pharmaceutical manufacturing, demonstrating the critical role of automation and industrial digitalisation in scaling injectable-therapy production.
